Does Female Viagra Exist?

A new pill dubbed ‘the female Viagra’ could boost women’s sex lives, according to scientists.

The herbal pill called Lady Prelox has been found to significantly raise a woman’s sexual pleasure. It is being sold by high-street chain Holland & Barrett.
The pink pill contains a supplement containing an extract from French pine bark called pycnogenol and goes on sale this month. Manufacturers claim the supplement is the female version of the little blue pill – Viagra – the erectile dysfunction drug.

But the £37.95 price tag for a pack of 60 little pink tablets is more likely to have women shrieking with horror especially as it is only enough to last a month because women have to take two a day.

The manufacturer of Lady Prelox, Nord Pharma, claims its product “boosts libido and increases arousal in women”, because it “encourages blood flow to the reproductive organs as well as the brain”

Read the full article at The Telegraph here.

Share

Maintaining a healthy sex life could make a difference in how couples cope with illness

Among older couples, physical illnesses can strain a marriage, but maintaining a healthy sex life could make a difference in how happily both partners cope, a new study suggests.

Researchers have long known the illnesses that come with age are linked to poorer marriage quality, but exactly why has not been clear. According to the new analysis, sexual intimacy is the link that keeps partners positive about their marriages in the face of difficult times, and a lack of sex makes matters worse.

The results “suggest that it may be important to stay sexually connected to protect” the quality of a marriage, lead author Adena Galinsky told Reuters Health.

Galinsky is a research affiliate of the University of Chicago’s Center on Demography and Economics of Aging in Illinois.

After analyzing data from 732 “couple units,” encompassing 1,464 individuals, most of whom were between 65 and 74 years old, Galinsky and a colleague found that sexual frequency was tied to relationship quality.

Read the full article here.

photo credit: www.oldretold.com

Share

AASECT Approved Post-Graduate Training for Diagnosis and Treatment of Sexual Dysfunctions. Sept 2014, NYC

Dear Colleagues,

I am delighted to announce the dates for the second cohort of the HAT training in New York City.

This program is approved by the American Association for Sexuality Educators, Counselors and Therapists (AASECT) for Continuing Education credits (CE) which could be used towards certification as a sex therapist by AASECT.

The HAT program is presented in three levels: Foundation, Intermediate and Advanced. It is based on the European model of assessment and care for sexual dysfunctions and designed for a wide range of therapists, counselors and licensed mental health professionals who would like to gain systematic knowledge and skills in working with sexual issues of individuals and couples.

I chose the name as a symbol of various ‘hats’ we wear as therapists to be able to address, assess and manage any sexuality and relationship issues our clients bring to the room.

This training includes principles from various disciplines such as: sexual-medicine, psychosexual therapy, cognitive behavioral therapy, neuro-linguistic programming, neuroscience and systems theory. The training will cover: Initial assessment techniques, history taking, formulation and treatment plan, educational approaches and props for various cultural groups, female and male sexual dysfunctions, blocks in the process and how to overcome them and ethical dilemmas of the therapist and how far one should go. Participants of all levels are welcome.

Please contact me for further information and to arrange for a telephone conversation to see if this course would fit your professional needs via the contact form [gravityform id=”2″ name=”General Contact” title=”false”]

The next Foundation cohort will start on September 26th, 2014 in Midtown New York City (9.30-11.30 am. Ten Fridays, once a month through 2014-15)

Information about the previous cohort and the layout of the Foundation course could be viewed here.

Share

Oral Contraceptives and eye disease (?)

Taking birth control pills for more than three years may increase a woman’s risk of developing the eye disease glaucoma, a new study suggests.

The findings are from an investigation involving more than 3,400 women aged 40 and older who took part in the U.S. National Health and Nutrition Examination Survey between 2005 and 2008.

“At this point, women who have taken oral contraceptives for three or more years should be screened for glaucoma and followed closely by an ophthalmologist, especially if they have any other existing risk factors,” said lead researcher Dr. Shan Lin, professor of clinical ophthalmology at the University of California, San Francisco.

Women who took birth control pills for longer than three years were twice as likely to have been diagnosed with glaucoma, according to the study. The findings were presented Monday at the annual meeting of the American Academy of Ophthalmology in New Orleans.

Read the full article here.

Share

FDA Approves Drug for Older Women Experiencing Painful Sex

Many women experience painful intercourse at some stage in their lives however as they get older this is a higher possibility with the decrease in hormonal levels which would impact the ability to get aroused (mostly physically which means less lubrication) and also with the thinning of the vaginal tissues. The U.S. Food and Drug Administration has approved a new drug to treat postmenopausal women who experience pain during sex, the agency announced Tuesday.

The drug Osphena (ospemifene) mimics the effects of estrogen on vaginal tissue, which can become thinner, drier and more fragile from menopause. The pill, taken with food once a day, makes vaginal tissue thicker and less fragile to reduce pain during sex (called dyspareunia).

“Dyspareunia is among the problems most frequently reported by postmenopausal women,” said Dr. Victoria Kusiak, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, in an FDA news release. “Osphena provides an additional treatment option for women seeking relief.”

Read the full article here.

Share